Champions Oncology Inc
NASDAQ:CSBR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Henkel AG & Co KGaA
XETRA:HEN3
|
DE |
|
E
|
E Star Commercial Management Co Ltd
HKEX:6668
|
CN |
|
U
|
Universal Cables Ltd
NSE:UNIVCABLES
|
IN |
|
H
|
Haier Smart Home Co Ltd
HKEX:6690
|
CN |
|
Eternal Ltd
NSE:ETERNAL
|
IN |
|
I
|
Innokaiz India Ltd
BSE:543905
|
IN |
|
S
|
Shenzhen CDL Precision Technology Co Ltd
SZSE:300686
|
CN |
Champions Oncology Inc
EPS (Diluted)
Champions Oncology Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Champions Oncology Inc
NASDAQ:CSBR
|
EPS (Diluted)
$0
|
CAGR 3-Years
10%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
19%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
EPS (Diluted)
$17
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Danaher Corp
NYSE:DHR
|
EPS (Diluted)
$5
|
CAGR 3-Years
-19%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Waters Corp
NYSE:WAT
|
EPS (Diluted)
$10
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Agilent Technologies Inc
NYSE:A
|
EPS (Diluted)
$4
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
EPS (Diluted)
$7
|
CAGR 3-Years
11%
|
CAGR 5-Years
41%
|
CAGR 10-Years
10%
|
|
Champions Oncology Inc
Glance View
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
See Also
What is Champions Oncology Inc's EPS (Diluted)?
EPS (Diluted)
-0.2
USD
Based on the financial report for Jan 31, 2026, Champions Oncology Inc's EPS (Diluted) amounts to -0.2 USD.
What is Champions Oncology Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
19%
The average annual EPS (Diluted) growth rates for Champions Oncology Inc have been 10% over the past three years , -16% over the past five years , and 19% over the past ten years .
